Effects of Carnosine Supplementation on Carnosine Concentrations in Muscles and Blood Biochemical Indices of Rats

Hae-Chang Yi¹, Mi Young Kim¹, Changsun Choi¹,², Young-Nam Kim³, Chan-Kyu Han⁴, and Bog-Hieu Lee¹,²*

¹Department of Food and Nutrition, Chung-Ang University, Anseong 456-756, Korea
²School of Food Science and Technology, Chung-Ang University, Anseong 456-756, Korea
³Department of Food and Nutrition, Duksung Women’s University, Seoul 132-714, Korea
⁴Biogeront Technology Research Group, Korea Food Research Institute, Seongnam 463-746, Korea

Abstract

This study evaluated the effects of carnosine supplementation on carnosine concentration in muscles and blood biochemical indices of rats. Thirty-two eight-week-old Sprague-Dawley male rats were randomly divided into a control group (CON) as well as three carnosine-treated groups. The carnosine-treated groups included groups fed diets composed of 0.01% carnosine (LC), 0.1% carnosine (MC), and 1.0% carnosine (HC). Body weight gain, food intake, feed efficacy rate, protein efficacy rate, and organ weights were not significantly different among the groups. In all groups, the mean carnosine levels in gastrocnemius muscles were higher than the mean carnosine levels in soleus muscles. Carnosine concentrations in soleus muscles and gastrocnemius muscles were significantly higher in the HC group compared to all other groups (p<0.05).

Serum triglyceride and LDL-cholesterol concentrations in all of the carnosine-supplemented groups were significantly lower than those of the control group (p<0.05), while HDL-cholesterol levels were significantly higher than those of the control group (p<0.05). Aspartate aminotransferase levels in rats supplemented with carnosine were significantly higher than those of the control group. In conclusion, diets supplemented with high levels of carnosine can increase carnosine concentrations in skeletal muscles, which might contribute to increased exercise capacity. Furthermore, these findings suggest that high levels of dietary carnosine improve the lipid profile of rats by lowering blood LDL-cholesterol and increasing HDL-cholesterol levels.

Key words: carnosine, muscle carnosine, lipid profile, rats

Introduction

Carnosine (β-alanyl-L-histidine) is a dipeptide of β-alanine and L-histidine that is found in the skeletal muscle, brain, and liver of many vertebrates (Jackson and Lenny, 1996; Plowman and Close, 1988). It has several functions including protection of membranes, pH buffering, metal chelating, and inhibition of oxidative protein modification by carbonyl compounds (Guiotto et al., 2005).

Exercise leads to an accumulation of metabolites with accompanying increases in free radical production (Ji, 1995; Mastaloudis et al., 2001). Reactive oxygen species are known to be a primary cause of exercise-induced disturbances in muscle homeostasis associated with muscle fatigue (Bailey et al., 2001; Petersen et al., 2001). Carnosine may act as an antioxidant in vivo and in vitro by quenching singlet oxygen and hydroxyl radicals released during exercise (Decker, 1995; Klebanov et al., 1997; Mastaloudis et al., 2001) and enhancing the antioxidative effect of vitamin E (Boldyrev, 1990). The soleus muscle is preferentially activated in the concentric phase, whereas the gastrocnemius muscle is preferentially activated in the eccentric phase and is activated at higher lengthening velocities (Nardone et al., 1989). Therefore, the high concentration of carnosine in the soleus and gastrocnemius muscles might reduce reactive oxygen and the degree of exhaustion, and increase power output during high-intensity exercise.

Some studies have shown that carnosine concentrations in rat tissues can be increased through dietary supplementation (Maynard et al., 2001) and carnosine concentrations in skeletal muscles are reduced by dietary L-histidine deficiencies (Dunnett and Harris, 1999; Tamaki et al., 1984). However, the results of dietary carnosine supple-
Carnosine Effects on Muscle and Biochemical Indices

585

mentation on carnosine concentrations in muscles are inconsistent. Tamaki et al. (1984) reported that a 0.875% carnosine dietary supplementation in rats did not increase carnosine concentrations in the heart, liver, and skeletal muscle. But, a high level (1.8%) of carnosine supplementation resulted in significant increases of carnosine in the soleus muscle (Maynard et al., 2001).

In addition, carnosine prevents low density lipoprotein (LDL) oxidation from copper-induced oxidative damage in vitro (Bogardus and Boissonneault, 2000; Decker et al., 2001) and glucose-induced oxidative and glycative damage in animal tissues (Lee et al., 2005). However, it is not reported that the supplementary intake of carnosine change blood and lipid profile including triglycerides, total cholesterol, LDL cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) in vivo. Functionality of carnosine obtained from muscle foods should be evaluated in vivo model.

Therefore, the purpose of this investigation was to examine whether gradually increased carnosine supplementations (0.01%, 0.1%, and 1%) increase carnosine concentrations in skeletal muscles and improve lipid profiles in rats.

Materials and Methods

Experimental design and animal care

Thirty-two male Sprague-Dawley rats supplied by Hanlim Experimental Animal Laboratory (Korea) with an average initial body weight of 152.5±4.8 g were randomly assigned to four groups, each composed of eight rats. The rats were kept individually in stainless-steel cages in a room controlled for temperature (22±1°C), relative humidity (50-60%), and light (12-hour light/dark cycle). All experimental protocols followed established guidelines for the care and handling of laboratory animals and were approved by the Institutional Animal Ethics Committee of the Chung-Ang University. After a two week adaptation, the four groups were fed four different diets for four weeks. The control group (CON) was fed a CRF-1 diet (regular laboratory pellet chow; Oriental Yeast, Japan). The three carnosine-supplemented groups were fed three different diets containing 0.01% carnosine (low carnosine, or LC), 0.1% carnosine (medium carnosine, or MC), and 1% carnosine (high carnosine, or HC). Carnosine was purchased from Sigma (USA).

The rats were allowed free access to the experimental food and deionized water. There were no significant differences among the groups in body weight at the start of the experiment. Body weight and food consumption were measured every week, and food efficacy rate (FER) and protein efficacy rate (PER) were also calculated weekly.

After four weeks of ad libitum feeding, the animals were fasted overnight, anesthetized with ethyl ether, and sacrificed. Liver, heart, kidneys, spleen, soleus muscle, and gastrocnemius muscle were removed and weighed. Blood was collected immediately from the abdominal aorta, and serum was obtained by blood centrifugation (3,000 rpm, 10 min, 4°C). All of the collected samples were stored at -70°C until analysis.

Carnosine concentrations in muscle tissue

All reagents used for carnosine analysis were HPLC grade. Acetonitrile and methanol were obtained from JT Baker (USA). Acetic acid and tetrahydrofuran (THF) were obtained from Merck (Germany). Carnosine was purchased from Sigma (USA).

Carnosine concentrations in muscle tissue were analyzed by a modification of Aristoy's method (Aristoy et al., 2004). The tissue sample was homogenized at 10,000 rpm with five-fold volume of triple-distilled water. The homogenate was centrifuged at 6,000 rpm for 30 minutes at 4°C and the supernatant was filtered through a glass wool. The 300 µL of supernatant was deproteinised by adding 900 µL of methanol and left at 4°C for 15 minutes. The sample was centrifuged (12,000 rpm, 4°C) for three minutes and the supernatant (20 µL) was analyzed for carnosine.

The HPLC system (Gilson, France) consisted of a Gilson 305 pump with fluorescence detector (Gilson 121 fluorometer). The column was a Haisil HL C18 (250×4.6 mm, Higgins Analytical, Inc., USA) and a binary mobile phase system was used. Solvent A was 515 mL of 50 mM acetate buffer and 350 mL water. Four M NaOH was then added until the pH reached 4.3, at which point 100 mL methanol and 30 mL THF were added. Solvent B was 290 mL of 50 mM acetate buffer, 195 mL water, 495 mL acetonitrile, and 25 mL THF. The gradient was 16% B, which increased to 17% in 2.5 min, to 20% in 5 min, to 30% in 7 min, to 100% in 5 min, and finally decreased to 16% in 5 min. The flow rate was 1.3 mL/min. Excitation and emission wavelengths were 340 and 470 nm, respectively.

Biochemical analysis

Triglyceride, total cholesterol, and HDL-C concentrations in serum were determined using enzymatic kits (Somang Co., Korea). LDL-C concentrations were calcu-
lated by the Friedewald equation (Friedewald et al., 1972). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using an auto analyzer (SPOTCEM™, Japan).

Statistical analysis
Statistical analysis was performed with SPSS software program 12.0 (SPSS, Inc., USA). Data are presented as mean±SD. The effects of carnosine supplementation were determined using one-way ANOVA tests followed by post-hoc test (Duncan’s multiple range test) for mean comparison. A p value <0.05 was considered significant.

Results

Body Weight, FER, and PER
Body weight, food intake, FER, PER, and organ weights of rats are presented in Table 1. There were no significant differences in initial and final body weights among the groups (p>0.05). Food intake, FER, and PER were not significantly different among the groups.

Organ Weights
Table 2 shows the organ weights of the groups. The weights of the liver, heart, kidneys, spleen, and testicles in the carnosine-supplemented groups did not significantly differ from those in the CON groups. The weight of the soleus muscle and gastrocnemius muscle were not significantly different among the groups.

Concentrations of Carnosine in Muscle Tissue
Carnosine concentrations in muscle tissues are shown in Table 3. Carnosine concentrations in the soleus muscle and gastrocnemius muscle were highest in the HC group (p<0.05), whereas carnosine concentrations in the soleus and gastrocnemius in the LC and MC groups were not significantly different compared to the CON group.

Biochemical analysis
Biochemical indices in serum are presented in Table 4. The triglyceride concentrations of the carnosine-supplemented groups were lower than that of the CON group (p<0.05), and decreased as carnosine-supplementation increased. There were no significant differences in serum total cholesterol levels among the groups. That said, the carnosine-supplemented groups had significantly higher concentrations of HDL-C and significantly lower concentrations of LDL-C compared to the CON group (p<0.05).

Table 1. Body weight, food intake, feed efficacy rate (FER) and protein efficacy rate (PER) in rats fed a carnosine-supplemented diet for four weeks

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group (g)</th>
<th>CON</th>
<th>LC</th>
<th>MC</th>
<th>HC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight (g)</td>
<td></td>
<td>303.3±33.9</td>
<td>302.3±20.9</td>
<td>306.8±30.5</td>
<td>304.2±16.2</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td></td>
<td>429.5±31.0</td>
<td>421.6±21.0</td>
<td>422.7±16.9</td>
<td>420.9±10.0</td>
</tr>
<tr>
<td>Mean body weight (g)</td>
<td></td>
<td>371.1±54.7</td>
<td>366.5±51.7</td>
<td>369.7±50.3</td>
<td>366.3±50.6</td>
</tr>
<tr>
<td>Mean food intake (g/day)</td>
<td></td>
<td>2.56±1.37</td>
<td>2.49±1.16</td>
<td>2.47±1.06</td>
<td>2.79±1.19</td>
</tr>
<tr>
<td>FER (g gain/g feed)</td>
<td></td>
<td>0.24±0.10</td>
<td>0.23±0.08</td>
<td>0.24±0.09</td>
<td>0.23±0.09</td>
</tr>
<tr>
<td>PER (g gain/g feed)</td>
<td></td>
<td>1.04±0.45</td>
<td>1.03±0.33</td>
<td>1.04±0.38</td>
<td>1.02±0.38</td>
</tr>
</tbody>
</table>

1) Values are mean±SD
2) CON, control; LC, low-dose (0.01%) carnosine; MC, medium-dose (0.1%) carnosine; HC, high-dose (1%) carnosine

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group (g/kg body weight)</th>
<th>CON</th>
<th>LC</th>
<th>MC</th>
<th>HC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>31.26±1.89</td>
<td>32.04±2.26</td>
<td>31.77±2.50</td>
<td>30.28±2.48</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>3.34±0.34</td>
<td>3.10±0.20</td>
<td>3.11±0.36</td>
<td>3.04±0.19</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>3.58±0.27</td>
<td>3.55±0.29</td>
<td>3.54±0.29</td>
<td>3.60±0.29</td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>2.02±0.35</td>
<td>1.87±0.17</td>
<td>1.97±0.21</td>
<td>1.84±0.34</td>
<td></td>
</tr>
<tr>
<td>Testicle</td>
<td>3.53±0.38</td>
<td>3.57±0.30</td>
<td>3.77±0.34</td>
<td>3.77±0.21</td>
<td></td>
</tr>
<tr>
<td>Muscle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soleus muscle</td>
<td>0.46±0.05</td>
<td>0.49±0.04</td>
<td>0.47±0.04</td>
<td>0.46±0.06</td>
<td></td>
</tr>
<tr>
<td>Gastrocnemius muscle</td>
<td>2.05±0.35</td>
<td>1.88±0.15</td>
<td>1.96±0.13</td>
<td>2.00±0.17</td>
<td></td>
</tr>
</tbody>
</table>

1) Values are mean±SD
2) CON, control; LC, low-dose (0.01%) carnosine; MC, medium-dose (0.1%) carnosine; HC, high-dose (1%) carnosine
There was no significant difference in concentrations of total protein among the groups. Serum AST concentrations in the carnosine-supplemented groups were significantly higher than in the CON group ($p<0.05$), and serum AST levels tended to increase as carnosine levels increased in the diet. There was no significant difference in serum ALT concentrations.

**Discussion**

In this study, carnosine showed the beneficial effects in vivo model. The supplementation of carnosine showed the positive dose-dependent relationship with muscle carnosine concentration of rats. This study also found that carnosine intake improved the lipid profile and blood biochemical indices of rats dose-dependently without significant change of body weight and food intake. No et al. (2004) also reported that oral administration of 25 mg/kg body weight of carnosine for eight weeks did not have an effect on body weight. These findings are consistent with several studies (No et al., 2004; Sato et al., 2008). Similarly, it is reported that beta-alanine supplementation increases the muscle carnosine and improves exercise capacity in elderly subjects (del Favero et al., 2012). Because carnosine and anserine are 55 mg/100 mL and 88 mg/100 mL boiled meat homogenate in chicken, respectively (Hermanuseen et al., 2012), carnosine could be used or developed as a functional food ingredient obtained from chicken meat.

Generally, carnosine levels are higher in fast-twitch (FT) muscles and lower in slow-twitch (ST) muscles (Bump et al., 1990; Dunnett et al., 1997). The gastrocnemius muscle usually contains a larger proportion of FT muscle fibers, while the soleus muscle primarily consists of ST muscle fibers. In the present study, mean carnosine levels in gastrocnemius muscles were higher than the mean carnosine levels in the soleus muscle of all groups. In addition, rats fed the HC diet had the highest concentrations of carnosine in both the soleus and gastrocnemius muscles. Tamaki et al. (1984) reported that 0.9% dietary carnosine intake did not significantly increase carnosine levels in muscles. But, in the present study, 1% dietary carnosine intake significantly increased carnosine levels in both the soleus and gastrocnemius muscles. A study conducted by Maynard et al. (2001) found that only the highest carnosine dose (1.8%), fed over a period of eight

### Table 3. Carnosine concentrations in skeletal muscle of rats fed a carnosine-supplemented diet for four weeks

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group&lt;sup&gt;2&lt;/sup&gt;</th>
<th>CON</th>
<th>LC</th>
<th>MC</th>
<th>HC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soleus muscle (mg/g)</td>
<td></td>
<td>1.52±0.23&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.57±0.18&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.56±0.36&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.14±0.42&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gastrocnemius muscle (mg/g)</td>
<td></td>
<td>2.76±0.55&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.70±0.36&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.81±0.58&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.44±0.19&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1</sup>Values are mean±SD  
<sup>2</sup>CON, control; LC, low-dose (0.01%) carnosine; MC, medium-dose (0.1%) carnosine; HC, high-dose (1%) carnosine  
<sup>a</sup>Different superscripts in the same row indicate that the data are significantly different per Duncan’s multiple range test ($p<0.05$).

### Table 4. Biochemical indices in serum of rats fed a carnosine-supplemented diet for four weeks

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group&lt;sup&gt;2&lt;/sup&gt;</th>
<th>CON</th>
<th>LC</th>
<th>MC</th>
<th>HC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid profiles (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride</td>
<td></td>
<td>31.50±12.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>28.10±16.9&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>24.70±7.8&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>16.00±8.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td></td>
<td>55.40±6.1</td>
<td>56.60±10.8</td>
<td>56.60±11.3</td>
<td>64.80±7.1</td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td></td>
<td>22.70±11.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>42.20±7.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>46.60±10.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>48.70±9.9&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>LDL-cholesterol</td>
<td></td>
<td>26.20±8.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>16.90±5.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>17.80±7.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>17.50±11.4&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Total protein (g/dL)</td>
<td></td>
<td>5.88±0.60</td>
<td>6.20±0.73</td>
<td>6.09±0.45</td>
<td>5.65±0.68</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td></td>
<td>0.40±0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.59±0.23&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.56±0.15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.63±0.22&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AST&lt;sup&gt;3&lt;/sup&gt;(IU/L)</td>
<td></td>
<td>114.50±16.80&lt;sup&gt;a&lt;/sup&gt;</td>
<td>175.13±30.08&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>179.43±26.49&lt;sup&gt;b&lt;/sup&gt;</td>
<td>218.88±40.65&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALT&lt;sup&gt;4&lt;/sup&gt;(IU/L)</td>
<td></td>
<td>11.17±2.86</td>
<td>19.63±6.52</td>
<td>21.00±6.73</td>
<td>18.25±12.78</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td></td>
<td>14.94±3.08</td>
<td>14.76±2.75</td>
<td>15.29±1.64</td>
<td>14.88±1.15</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td></td>
<td>43.24±21.69</td>
<td>36.79±6.61</td>
<td>37.49±4.38</td>
<td>38.13±2.43</td>
</tr>
</tbody>
</table>

<sup>1</sup>Values are mean±SD  
<sup>2</sup>CON, control; LC, low-dose (0.01%) carnosine; MC, medium-dose (0.1%) carnosine; HC, high-dose (1%) carnosine  
<sup>3</sup>Aspartate aminotransferase  
<sup>4</sup>Alanine aminotransferase  
<sup>a</sup>Different superscripts in the same row indicate that the data are significantly different per Duncan’s multiple range test ($p<0.05$).
weeks, increased muscle carnosine content in the soleus muscle. Also, Tamaki et al. (1984) reported that 1.8% dietary carnosine increased carnosine concentrations approximately twice as much in the gastrocnemius muscle when compared carnosine concentrations in the gastrocnemius muscles of the control group. Increased carnosine concentration in the muscles may result in improved athletic performance. β-Alanine, one component of carnosine, was provided to human male subjects for four and 10 weeks and resulted in increased carnosine concentrations in the vastus lateralis muscle and improved performance in a bicycle capacity test (Hill et al., 2007). These results are in line with findings by Suzuki et al. (2002) that showed positive correlations between carnosine concentrations and mean power per body weight during high-intensity exercise (30S Wingate test).

In this study, the triglyceride level of the HC group was significantly lower than that of the CON group. Lee et al. (2005) reported that a dietary supplementation of 0.5 or 1 g/L of carnosine in water caused a dose-dependent decrease in triglyceride concentrations in the liver and heart, and that 1 g/L carnosine reduced total cholesterol levels in the liver and heart of streptozotocin-induced diabetic mice. However, in the present study, there was no significant difference in serum total cholesterol levels among the groups. Duthie and Bellizzi (1999) suggested that antioxidant supplementation might help to increase circulating HDL-cholesterol concentrations. Carnosine is thought to have antioxidant properties due to its ability to quench single molecular oxygen and scavenge superoxide radicals (Gariballa and Sinclair, 2000; Pavlov et al., 1993). Therefore, a carnosine supplement may have a beneficial effect on HDL-C concentrations in blood. In this study, all of the carnosine-supplemented groups had significantly higher concentrations of HDL-C than that of the CON group (p<0.05), and the HDL-C levels tended increase with increasing amounts of supplemented carnosine.

All of the carnosine-supplemented groups in this study had significantly lower concentrations of LDL-C than that of the CON group (p<0.05), suggesting that carnosine supplementation may decrease LDL-C in blood. Lipids are very susceptible to attack by free radicals and oxidized-LDL species (Takahashi et al., 2005). LDL molecules are the major cholesterol carriers in blood and appear to be involved in the development of atherosclerosis. Lee et al. (2005) found that carnosine effectively protected LDL against glucose-induced oxidation in humans by acting as a scavenger of free radicals in LDL and retarding LDL oxidation. It has also been suggested that carnosine (3 µM) inhibits copper-promoted LDL (20 µg of protein/mL) oxidation (Decker et al., 2001), and effectively suppresses LDL oxidation by copper or peroxyl radicals in an ex vivo test (Bogardus and Boissonneault, 2000).

Wolford et al. (1986) indicated that the AST reference range for rats less than six months old was approximately 68-128 IU/L. Mean AST levels in this study were significantly higher than this reference range, with the exception of the CON group (p<0.05). AST levels were highest in the HC group. ALT concentrations of all experimental groups tended to be higher than ALT concentrations in the CON group. Total bilirubin levels in the HC group were significantly higher than that of the CON group. These elevated bilirubin levels suggest that a dietary supplement of 1% carnosine over a period of four weeks may induce liver damage in rats. However, Liu et al. (2008) reported that ingestion of carnosine in water (1 g/L) for four weeks did not affect AST levels. Several other studies have also shown that carnosine supplementation protects the liver against ethanol (Artun et al., 2010) and thioacetamide (Aydin et al., 2010), both of which are widely used to induce liver injuries in experiments. Carnosine also appears to protect the liver from acetaminophen (Yan et al., 2009), which can also cause liver injuries if administered above recommended dosages. That said, Ibrahim et al. (2008) indicated that moderate levels of dietary carnosine (200 mg or 1000 mg carnosine/kg food) in rats had no significant effect on the incidence of myodegeneration and susceptibility of erythrocytes to hemolytic stress or oxidative stress in the liver. Sato et al. (2008) reported that the no-observed-adverse-effect level for rats fed chicken breast extract containing at least 35% carnosine and anserine was considered to be 2000 mg/kg body weight/day. When the carnosine intake in this study is converted to that dose unit, the LC group consumed 8.7-12.1 mg/kg body weight/day of carnosine and the HC group was 870.8-1204.1 mg/kg body weight/day of carnosine. Thus, results regarding the effects of carnosine supplementation on the liver of rats are still controversial.

In conclusion, the findings in this study suggest that high-dose (1%) carnosine supplementation increases carnosine concentrations in muscles. Low levels of dietary carnosine supplementation (0.01% carnosine) may improve lipid profiles by lowering LDL-C and increasing HDL-C levels in blood. However, several biochemical indices used to indicate liver damage including AST, ALT, and total bilirubin increased with carnosine supplementation,
particularly high-dose carnosine. Therefore, further research is needed to determine the effects of carnosine supplementation on the liver. Future studies should explore the minimum amount of carnosine required to increase carnosine concentrations in muscles and improve lipid profiles, without negatively impacting biochemical indices related to liver damage.

Acknowledgement

This research was supported by the Chung-Ang University Research Grant in 2012.

References


(Received 2012.7.4/Revised 2012.8.31/Accepted 2012.9.6)